Left wing parties in India have secured a series of amendments that water down the protection given to product patents in the country's Patent Act. But politicians and health activists are still ...

India promised to protect intellectual property when it signed up to the World Trade Organization’s rules in 2005. Yet recent court decisions suggest the country still has a long way to go before ...

Archana Shanker and Drishi Kaur of Anand and Anand discuss the often ambiguous requirements of section 8 of the Indian Patents Act The disclosure of foreign filing to the Indian Patent Office is a ...

The Patents (Amendment) Act 2005 was ratified by the Indian Parliament in April, and is effective from January 1. This amendment is the third to the Indian Patent Act of 1970. It also replaces the ...

The Pharmaceutical Research and Manufacturers of America (PhRMA) continues to flog India for what it termed as a 'Generally weak IP environment' in the country and has expressed concern over Section 3 ...

Equitable access to safe, effective, and affordable medicines remains a crucial public health challenge. According to the WHO, nearly two billion people worldwide—many in low- and middle-income ...

Cancer patients in India have reason to be relieved at a high court ruling this week which dismissed a petition by Swiss pharmaceuticals multinational corporation (MNC) Novartis challenging an Indian ...

The NCLAT ruled that the CCI cannot investigate disputes concerning patented products, asserting the Patent Act's precedence ...

The National Company Law Appellate Tribunal (NCLAT) on Thursday reaffirmed that the Competition Commission of India (CCI) has ...

The Indian government is moving towards approving a law that will create a framework for universities to patent their discoveries. Currently, ownership of innovations made through government-funded ...

The Supreme Court has transferred a patent infringement suit filed by Eureka Forbes Limited before the Delhi High Court to ...

On Monday the pharmaceutical company Novartis will bring an action against the Indian government in the High Court in Chennai, claiming that it should have been granted a patent for its drug Glivec.